Ever get behind in submitting your annual report for approved applications? Just too much to do and they slip a bit. The next thing you know you are buried and the annual reports you placed temporarily on the back burner, become the current burning issue. Yesterday in a Federal Register pre-publication notice (here), the FDA announced it “is proposing to withdraw approval of new drug application (NDA) 206679 for Flolipid suspension, 20 milligrams (mg)/5 milliliters (mL) and 40 mg/5 mL and is announcing an opportunity for the NDA holder, Salerno Pharmaceuticals to request a hearing on this proposal”. The product is an oral suspension of simvastatin.

The Agency’s notice is providing the sponsor of the application an opportunity for a hearing on the proposal to withdrawal the application. This is something you rarely see and most firms keep their annual report up to date. FDA usually will let firms know that they are behind on their annual reporting but occasionally, the Agency finds that the sponsor fails to heed the warning. That is what appears to have happened in this instance as the FDA states the firm “has repeatedly failed to submit the required annual reports and has not responded to the Agency’s request for submission of the reports”.

While it is not known if the product being marketed, the product does appear in the active Section of the Orange Book. The Agency only takes this type of action when it has exhausted other avenues to let firms know the importance of making timely annual report submissions. If your firm has fallen behind in annual report submission we at Lachman Consultants can help. Don’t let the FDA get to this last resort position by threatening to withdraw approval of your asset(s). Reach out to us at LCS@lachmanconsultants.com and we can help you get your annual reports back on track.